Haemonetics Corporation
$ 87.84
3.32%
07 Aug - close price
- Market Cap 3,868,159,000 USD
- Current Price $ 87.84
- High / Low $ 87.87 / 84.88
- Stock P/E 40.88
- Book Value 17.60
- EPS 2.08
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 88.58
- 52 Week Low 47.32
About
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$87.90
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-05 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-08 | 2023-11-02 |
| Reported EPS | 1.14 | 1.29 | 1.31 | 1.27 | 1.1 | 1.24 | 1.19 | 1.12 | 1.02 | 0.9 | 1.04 | 0.99 |
| Estimated EPS | 1.07 | 1.27 | 1.25 | 1.11 | 1.01 | 1.22 | 1.17 | 1.07 | 1.01 | 0.89 | 0.94 | 0.89 |
| Surprise | 0.07 | 0.02 | 0.06 | 0.16 | 0.09 | 0.02 | 0.02 | 0.05 | 0.01 | 0.01 | 0.1 | 0.1 |
| Surprise Percentage | 6.5421% | 1.5748% | 4.8% | 14.4144% | 8.9109% | 1.6393% | 1.7094% | 4.6729% | 0.9901% | 1.1236% | 10.6383% | 11.236% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HAE
2026-08-07 09:40:05
This article provides a technical analysis of Haemonetics Corp (HAE), detailing its current price momentum score of 4.19 and its trading range between a resistance level of $91.33 and a support level of $75.97. It evaluates various technical indicators, including MACD, RSI, and moving averages, offering buy, sell, or neutral signals, and concludes with a neutral signal based on today's moving averages and other technical indicators.
2026-08-06 19:11:29
BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $96 from $84, maintaining a Buy rating after the company reported strong first-quarter revenues and adjusted earnings per share that surpassed consensus estimates. All segments performed well, with Interventional Technologies returning to growth and Plasma revenue benefiting from market share gains. Despite a recent stock decline due to cautious outlook and margin pressures, Haemonetics raised its fiscal 2027 revenue guidance, and InvestingPro analysis suggests the stock remains undervalued.
2026-08-06 16:40:05
BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $96 from $84, maintaining a Buy rating, following the company's strong first-quarter revenue of $339.4 million and adjusted EPS of $1.14, both exceeding consensus estimates. All segments surpassed expectations, and the company raised its fiscal 2027 revenue growth guidance. Despite strong results, the stock recently declined due to investor concerns about a cautious outlook and margin pressures.
2026-08-06 10:11:56
Haemonetics (NYSE: HAE) announced that its financial results for the first quarter of fiscal 2027, which ended June 27, 2026, are now available on its Investor Relations website. The company will host an investor conference call and live webcast on August 6, 2026, at 8:00 a.m. ET to discuss these results, with a replay available for one year. Following the announcement, HAE's stock saw a moderate positive market reaction, gaining 3.30%.
2026-08-06 10:11:56
Haemonetics Corporation announced that its first quarter fiscal year 2027 financial results, for the period ending June 27, 2026, are now available on its Investor Relations website. The company will also host a conference call and webcast on August 6, 2026, at 8:00 a.m. ET to discuss these results. Supplemental earnings materials are also posted online for reference during the call.
2026-08-06 10:11:29
Haemonetics announced its first-quarter fiscal 2027 results, reporting net revenue of $339.4 million, a 5.6% year-over-year increase, and adjusted earnings per diluted share of $1.14. The company raised its full-year fiscal 2027 revenue and organic growth targets, attributing the strong performance to plasma share gains and momentum in Blood Management Technologies. Haemonetics also reiterated its guidance for adjusted operating margin expansion and free cash flow conversion.
